Revlimid lenalidomide: Additional Phase III data

Additional data from the double-blind, international Phase III MM-015 trial in 459 patients showed that about 3% of patients treated with Revlimid plus melphalan and prednisone followed by Revlimid as maintenance therapy developed secondary malignancies compared to 1% of patients receiving placebo. Data were presented at the American Society of Hematology meeting in Orlando. ...